Balance Sheet
Cash Flow Statement
AcquisitionsAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Beam Therapeutics (BEAM) Non-cash Items (2019 - 2025)

Beam Therapeutics (BEAM) has disclosed Non-cash Items for 7 consecutive years, with $53.8 million as the latest value for Q4 2025.

  • On a quarterly basis, Non-cash Items rose 44.81% to $53.8 million in Q4 2025 year-over-year; TTM through Dec 2025 was $53.8 million, a 44.81% increase, with the full-year FY2025 number at $53.8 million, up 44.81% from a year prior.
  • Non-cash Items was $53.8 million for Q4 2025 at Beam Therapeutics, up from $7.1 million in the prior quarter.
  • In the past five years, Non-cash Items ranged from a high of $300.6 million in Q4 2021 to a low of $1.7 million in Q2 2021.
  • A 5-year average of $34.8 million and a median of $6.0 million in 2024 define the central range for Non-cash Items.
  • Peak YoY movement for Non-cash Items: skyrocketed 220.16% in 2021, then tumbled 96.72% in 2022.
  • Beam Therapeutics' Non-cash Items stood at $300.6 million in 2021, then plummeted by 63.07% to $111.0 million in 2022, then plummeted by 53.46% to $51.7 million in 2023, then fell by 28.02% to $37.2 million in 2024, then soared by 44.81% to $53.8 million in 2025.
  • Per Business Quant, the three most recent readings for BEAM's Non-cash Items are $53.8 million (Q4 2025), $7.1 million (Q3 2025), and $6.7 million (Q2 2025).